Grace Therapeutics, Inc. (GRCE)
1.87
+0.09
(+5.06%)
USD |
NASDAQ |
Nov 06, 10:25
Grace Therapeutics Net Income (Quarterly) : -15.79M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -15.79M |
| March 31, 2026 | -1.178M |
| December 31, 2025 | -2.315M |
| September 30, 2025 | -0.938M |
| June 30, 2025 | -3.362M |
| March 31, 2025 | 0.636M |
| December 31, 2024 | -4.155M |
| September 30, 2024 | -3.432M |
| June 30, 2024 | -2.617M |
| March 31, 2024 | -3.166M |
| December 31, 2023 | -2.391M |
| September 30, 2023 | -3.273M |
| June 30, 2023 | -4.023M |
| March 31, 2023 | -29.09M |
| December 31, 2022 | -3.889M |
| September 30, 2022 | -4.929M |
| June 30, 2022 | -4.524M |
| March 31, 2022 | -3.904M |
| December 31, 2021 | -3.778M |
| September 30, 2021 | 0.981M |
| June 30, 2021 | -3.118M |
| March 31, 2021 | -5.646M |
| December 31, 2020 | -3.22M |
| September 30, 2020 | -6.146M |
| June 30, 2020 | -4.666M |
| Date | Value |
|---|---|
| March 31, 2020 | |
| December 31, 2019 | -12.12M |
| September 30, 2019 | -21.16M |
| June 30, 2019 | -8.846M |
| March 31, 2019 | -12.64M |
| December 31, 2018 | -3.491M |
| September 30, 2018 | -17.39M |
| June 30, 2018 | -5.748M |
| March 31, 2018 | -6.436M |
| December 31, 2017 | -4.782M |
| September 30, 2017 | -3.596M |
| June 30, 2017 | -2.066M |
| February 28, 2017 | |
| November 30, 2016 | -1.808M |
| August 31, 2016 | -1.795M |
| May 31, 2016 | -2.426M |
| February 29, 2016 | -1.38M |
| November 30, 2015 | -1.660M |
| August 31, 2015 | -0.9704M |
| May 31, 2015 | -0.7798M |
| February 28, 2015 | -1.921M |
| November 30, 2014 | 2.695M |
| August 31, 2014 | -3.428M |
| May 31, 2014 | 1.234M |
| February 28, 2014 | -2.347M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 124.49M |
| Veru, Inc. | -6.988M |
| Johnson & Johnson | 210.00M |
| Eli Lilly & Co. | 6.451B |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 15.79M |
| EPS Diluted (Quarterly) | -0.9143 |
| Enterprise Value | 15.21M |
| Earnings Yield | -63.28% |
| Normalized Earnings Yield | -37.22 |